• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

489.75 -17.25 (-3.40%)
Delayed Quote Updated: 12:37 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 327,393
Open 507.55
Bid (Size) 489.60 (80)
Ask (Size) 490.16 (80)
Prev. Close 507.00
Today's Range 489.40 - 508.57
52wk Range 402.58 - 560.25
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Today 8:37 EDT
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it. 
Via The Motley Fool
News headline image
2 High-Flying Stocks on Our Watchlist and 1 We Question
October 12, 2026
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory

Performance

52-Week Range 12.6% below 52-week high
489.75
402.5852W Low 560.2552W High
1 Week 4.9% below 1-week high
496.321W Low 514.901W High

Vertex Pharmaceuticals (VRTX) traded between $402.58 and $560.25 over the past 52 weeks and last traded at $489.75, 12.6% below its 52-week high. Over the past week it ranged between $496.32 and $514.90.

Past 12 Months
-2.5%
-5.7%
+2.0%
+11.3%
+8.3%
+20.2%
1W -$12.56
1M -$29.76
3M +$9.50
6M +$49.70
YTD +$37.62
1Y +$82.38

VRTX was +20.2% over the past year, +11.3% over six months, +8.3% year to date, -2.5% in the last week.

12 Months vs Market
VRTX
+20.2%
DIA
+12.1%
SPY
+17.3%
QQQ
+23.5%
IWM
+13.1%

Over the past 12 months VRTX returned +20.2% versus DIA (Dow) +12.1%, SPY (S&P 500) +17.3%, QQQ (Nasdaq 100) +23.5% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 0.29× 3-mo avg
Today 327,393 3-mo avg 1.1M
1W
1.1M
1M
1.1M
3M
1.1M
6M
1.3M
YTD
1.4M
1Y
1.4M

VRTX most recently traded 327,393 shares against a 3-month average daily volume of 1.1M.

More News

Read More
News headline image
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
October 09, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right. ↗
October 09, 2026
Via The Motley Fool
News headline image
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
October 07, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Safe-and-Steady Stocks with Promising Prospects and 1 We Turn Down
October 05, 2026
Via StockStory
Topics Energy
News headline image
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
October 04, 2026
Via The Motley Fool
News headline image
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? ↗
October 01, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. ↗
September 29, 2026
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Target This Week and 1 We Avoid
September 28, 2026
Via StockStory
News headline image
2 Healthcare Stocks That Just Delivered Great News for Investors ↗
September 26, 2026
Via The Motley Fool
News headline image
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 24, 2026
Via The Motley Fool
News headline image
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
September 22, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026 ↗
September 20, 2026
Via The Motley Fool
News headline image
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? ↗
September 18, 2026
Via The Motley Fool
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
September 18, 2026
Via StockStory
Topics Stocks
News headline image
Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗
September 17, 2026
Via The Motley Fool
News headline image
My Top 5 Favorite Stocks for an Uncertain Market ↗
September 16, 2026
Via The Motley Fool
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
September 15, 2026
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗
September 14, 2026
Via MarketBeat
News headline image
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
September 14, 2026
Via The Motley Fool
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Brush Off
September 14, 2026
Via StockStory
News headline image
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis ↗
September 12, 2026
Via MarketBeat
News headline image
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference ↗
September 12, 2026
Via MarketBeat
News headline image
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Vertex Pharmaceuticals publicly traded?
Yes, Vertex Pharmaceuticals is publicly traded.
What exchange does Vertex Pharmaceuticals trade on?
Vertex Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Vertex Pharmaceuticals?
The ticker symbol for Vertex Pharmaceuticals is VRTX on the Nasdaq Stock Market
What is the current price of Vertex Pharmaceuticals?
The current price of Vertex Pharmaceuticals is 489.75
When was Vertex Pharmaceuticals last traded?
The last trade of Vertex Pharmaceuticals was at 10/13/26 12:37 PM ET
What is the market capitalization of Vertex Pharmaceuticals?
The market capitalization of Vertex Pharmaceuticals is 127.05B
How many shares of Vertex Pharmaceuticals are outstanding?
Vertex Pharmaceuticals has 127B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap